Increased [Ca2+]SR
|
Decreased [Ca2+]SR
|
(Lukyanenko et al., 1996; Györke and Györke, 1998; Györke et al., 2002) |
(Lukyanenko et al., 1996; Györke and Györke, 1998; Györke et al., 2002) |
RYR2 phosphorylation at PKA or CaMKII sites |
Calstabin2 (FKBP 12.6) binding |
(Valdivia et al., 1995; Li et al., 1998; Marx et al., 2000) |
(Marx et al., 2000; Wehrens et al., 2003) |
Caffeine |
Tetracaine |
(Rousseau and Meissner, 1989; O’Neill and Eisner, 1990; Venetucci et al., 2007) |
(Xu et al., 1993; Overend et al., 1997) |
RYR2 oxidation (ROS) |
Anti-oxidation |
(Hidalgo et al., 2002; Terentyev et al., 2008) |
(Hidalgo et al., 2002; Terentyev et al., 2008) |
RYR2 CPVT mutations |
|
(Marks et al., 2002; Wehrens et al., 2003) |
|
Calsequestrin mutations |
|
(Postma et al., 2002; Eldar et al., 2003; di Barletta et al., 2006; Knollmann et al., 2006) |
|
Triadin |
|
(Valdivia et al., 1995; Li et al., 1998; Marx et al., 2000; Györke and Terentyev, 2008; Chopra et al., 2009) |
|
RYR2 nitrosylation |
|
(Xu et al., 1998; Sun et al., 2008; Bellinger et al., 2009) |
|